BioCryst Q3 revenue rises 13% on ORLADEYO sales

Overview

• U.S. rare disease drugmaker's Q3 revenue rose 13% yr/yr, driven by ORLADEYO sales and CareMed transition

• Q3 net income increased significantly from a year earlier

• Company maintained 2026 ORLADEYO revenue guidance, raised total revenue outlook for the year

Outlook

• BioCryst maintains 2026 ORLADEYO revenue guidance of $625 mln to $645 mln

• Company raises 2026 total revenue guidance to $715 mln-$730 mln

• Company lowers 2026 non-GAAP operating expense guidance to $415 mln-$425 mln

Result Drivers

• CAREMED TRANSITION - Co said Q3 revenue growth benefited from the transition to CareMed as its sole-source specialty pharmacy partner, which built initial inventory of ORLADEYO to support patient demand

• ORLADEYO PELLET LAUNCH - Co said launch of ORLADEYO oral pellets in pediatric patients began in August, with early reimbursement strong and new prescriptions ahead of expectations

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for BioCryst Pharmaceuticals, Inc. is $17.50, about 104.2% above its November 3 closing price of $8.57

Reuters Recommended Reads

• Nov 2 - Syndax Pharmaceuticals Q3 revenue rises 82% on cancer drug sales

• Nov 2 - Travere Q3 product sales nearly double on FILSPARI growth

• Nov 3 - Mirum Pharmaceuticals Q3 net product sales surge, outlook raised

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)